Eurofins’ US Clinical Diagnostics delivers complete solutions for transplant patients
David Morgan, Senior Vice President, Eurofins Clinical Diagnostics, DavidMorgan@eurofinsUS.com
Determining what’s happening inside the body of a transplant patient is a constant balancing act for physicians. Is it rejection, infection, toxicity?
With the recent launches of Transplant Genomics’ TruGraf® and Viracor’s TRAC™ Kidney to the US Clinical Diagnostics’ transplant portfolio, Eurofins is now uniquely positioned to serve kidney transplant patients with complete testing solutions for managing rejection, infection, and immunosuppression to support successful outcomes.
TruGraf® Blood Gene Expression Test is the first and only biomarker-guided blood monitoring assay to rule out “silent” or subclinical rejection for patients with stable renal function. For kidney patients with no symptoms, this is a game-changing alternative to invasive and costly organ surveillance biopsies. TruGraf® is covered by Medicare.
Viracor TRAC™ Kidney is a noninvasive donor-derived cell-free DNA (dd-cfDNA) blood test for evaluating “active” or acute rejection. The current gold standard method of rejection diagnosis is biopsy. TRAC™ utilises a liquid biopsy to measure the percentage of dd-cfDNA in the transplant recipient’s plasma and eliminates potential complications that biopsies can cause for the patient. Viracor has secured a Proprietary Laboratory Analyses (PLA) code for Viracor TRAC™.
In the simplest terms, if you were a transplant patient, you would want to have TruGraf® ordered for you to make sure your immune system is not “silently rejecting” your new kidney without any outward indication. Silent rejection impacts up to 25% of kidney transplant recipients, so it’s a substantial consideration. In similar fashion, if you had indications that active rejection of your kidney had already begun – possibly through a high creatinine test result – you would want to have TRAC™ Kidney ordered for you, as the acute rejection could be confirmed with a blood test instead of a biopsy procedure, which would include taking biopsies of your kidney undergoing rejection.
In striving for diagnostic efficiency and improved cost of care, these advances in transplant testing will make a big difference for the constituencies they serve – transplant patients, healthcare providers and payers. Moreover, offering vanguard testing that impacts transplant patient care further enhances our reputation in the market for innovation, scientific expertise and exceptional service.
Additionally, the diagnostic power of Eurofins’ VRL pre-transplant laboratory and Viracor’s robust infectious disease and therapeutic drug monitoring options will provide hospitals, physicians and organ procurement organisations with the most comprehensive transplant testing menu available in the U.S. Healthcare providers can now partner with a single diagnostic source for their transplant patients’ continuum of care.
For more information visit: www.eurofins.com/clinical-diagnostics/